Virios Therapeutics Llc
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for… Read more
Virios Therapeutics Llc (VIRI) - Total Assets
Latest total assets as of June 2024: $3.64 Million USD
Based on the latest financial reports, Virios Therapeutics Llc (VIRI) holds total assets worth $3.64 Million USD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Virios Therapeutics Llc - Total Assets Trend (2018–2023)
This chart illustrates how Virios Therapeutics Llc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Virios Therapeutics Llc - Asset Composition Analysis
Current Asset Composition (December 2023)
Virios Therapeutics Llc's total assets of $3.64 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 79.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2023)
This chart illustrates how Virios Therapeutics Llc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Virios Therapeutics Llc's current assets represent 100.0% of total assets in 2023, an increase from 64.3% in 2018.
- Cash Position: Cash and equivalents constituted 79.6% of total assets in 2023, up from 45.5% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Virios Therapeutics Llc Competitors by Total Assets
Key competitors of Virios Therapeutics Llc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Virios Therapeutics Llc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Virios Therapeutics Llc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Virios Therapeutics Llc is currently not profitable relative to its asset base.
Virios Therapeutics Llc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.27 | 8.83 | 0.19 |
| Quick Ratio | 7.27 | 8.83 | 0.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.14 Million | $ 4.07 Million | $ -1.30 Million |
Virios Therapeutics Llc - Advanced Valuation Insights
This section examines the relationship between Virios Therapeutics Llc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.33 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -50.2% |
| Total Assets | $4.17 Million |
| Market Capitalization | $206.50K USD |
Valuation Analysis
Below Book Valuation: The market values Virios Therapeutics Llc's assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Virios Therapeutics Llc's assets decreased by 50.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Virios Therapeutics Llc (2018–2023)
The table below shows the annual total assets of Virios Therapeutics Llc from 2018 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $4.17 Million | -50.23% |
| 2022-12-31 | $8.37 Million | -46.95% |
| 2021-12-31 | $15.78 Million | -49.87% |
| 2020-12-31 | $31.47 Million | +9862.88% |
| 2019-12-31 | $315.90K | +379.11% |
| 2018-12-31 | $65.94K | -- |